US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Articles published by Arena Pharmaceuticals, Inc.

News headline image
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Reports Third Quarter Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Reports Second Quarter Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA
News headline image
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
Tickers ARNA